Cinctive Capital Management LP reduced its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 71.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,065 shares of the company's stock after selling 23,029 shares during the quarter. Cinctive Capital Management LP's holdings in Structure Therapeutics were worth $246,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Spire Wealth Management acquired a new position in Structure Therapeutics in the fourth quarter worth $243,000. JPMorgan Chase & Co. lifted its position in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after buying an additional 25,500 shares in the last quarter. Barclays PLC grew its holdings in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after acquiring an additional 31,815 shares during the last quarter. Pier Capital LLC increased its position in Structure Therapeutics by 32.7% in the 3rd quarter. Pier Capital LLC now owns 134,291 shares of the company's stock valued at $5,894,000 after acquiring an additional 33,087 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Structure Therapeutics by 9.4% in the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock worth $30,991,000 after acquiring an additional 60,397 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on GPCR. JMP Securities reissued a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $81.29.
Check Out Our Latest Stock Analysis on Structure Therapeutics
Structure Therapeutics Stock Performance
NASDAQ:GPCR traded up $1.12 during mid-day trading on Wednesday, hitting $15.27. The company had a trading volume of 1,824,370 shares, compared to its average volume of 867,670. Structure Therapeutics Inc. has a fifty-two week low of $13.22 and a fifty-two week high of $62.74. The firm has a market cap of $875.63 million, a P/E ratio of -20.63 and a beta of -1.35. The business's fifty day moving average is $21.52 and its two-hundred day moving average is $29.57.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Equities analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.
About Structure Therapeutics
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Read More
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
